Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370547 | 1.00 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29367303 | 0.91 | CRBN (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22291652 | 0.91 | CRBN (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31736587 | 0.87 | IKZF2 (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31736939 | 0.87 | IKZF2 (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20233690 | 0.82 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20133101 | 0.82 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22291619 | 0.81 | DDB1 (0.55) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL24185741 | 0.81 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22737163 | 0.81 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116322780-A | Compounds and uses thereof | 福宏治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4188447-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885ALDH1A1 1387/4885 |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885ALDH1A1 1387/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885ALDH1A1 1387/4885 |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | BRD9, BRWD1, BRD2 | CRBN 60/4885DDB1 895/4885ALDH1A1 3268/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | CRBN 60/4885DDB1 895/4885ALDH1A1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.